VEGF is required for growth and survival in neonatal mice by Gerber, H. P. et al.
INTRODUCTION
The cardiovascular system is the first organ system to develop
and reach a functional state in an embryo (Hamilton et al.,
1962). The initial steps consist of ‘vasculogenesis’, the
differentiation of endothelial cell precursors, the angioblasts,
from the mesenchyme (Risau, 1995). The juvenile vascular
system evolves from the primary capillary plexus by
subsequent pruning and reorganization of endothelial cells in
a process called ‘angiogenesis’. This complex remodeling
process involves the recruitment of mural cells and starts in
almost all organ systems during late embryonic development
(Nehls and Drenckhahn, 1993; Patan et al., 1997). Although
vascularization occurs concomitantly to organ growth,
surprisingly little is known about the role of endothelial cells
and angiogenesis in regulating normal growth and organ
homeostasis during postnatal development.
Several positive regulators of angiogenesis have been
identified, including aFGF, bFGF, TGF- a , TGF- b , HGF, TNF-
a , VEGF, angiogenin, IL-8 and the angiopoietins (for a review,
see Carmeliet and Collen, 1998). Also, the a vb 3 integrin
pathway has been shown to play a role in angiogenesis (Brooks
et al., 1994). The negative regulators include thrombospondin
(Good et al., 1990), the 16 kDa fragment of prolactin (Clapp
et al., 1993), SPARC (Sage et al., 1995), angiostatin (O’Reilly
et al., 1994) and endostatin (O’Reilly et al., 1997). The
interplay between positive and negative regulators of
angiogenesis is thought to give rise to the complex patterns of
vascularization observed in different tissues and organs (Risau,
1997).
The endothelial cell-specific mitogen VEGF is a key
mediator of normal and abnormal angiogenesis (Ferrara and
Davis-Smyth, 1997). VEGF exerts its biological effects by
binding to its respective tyrosine kinase receptors VEGFR1
(Flt-1) and VEGFR2 (Flk-1/KDR), both of which are
expressed on endothelial cells. Mouse embryos null for either
receptor die in utero between days 8.5 and 9.5 (Fong et al.,
1995; Shalaby et al., 1995). Strong experimental evidence links
Flk-1/KDR activation to VEGF-induced mitogenesis and
angiogenesis (Ferrara and Davis-Smyth, 1997). In contrast, the
function of Flt-1 is less clear and recent studies have
unexpectedly shown that this receptor may perform its role in
angiogenesis primarily as a ligand binding molecule, rather
than as a signaling tyrosine kinase (Hiratsuka et al., 1998).
VEGF is essential for embryonic development and loss of even
a single VEGF allele results in embryonic lethality (Carmeliet
et al., 1996; Ferrara et al., 1996).
Several lines of evidence suggest that VEGF is not only a
mitogen but also a survival factor for newly formed blood
vessels. However, this pro-survival role in vivo has only been
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We employed two independent approaches to inactivate the
angiogenic protein VEGF in newborn mice: inducible, Cre-
loxP- mediated gene targeting, or administration of mFlt(1-
3)-IgG, a soluble VEGF receptor chimeric protein. Partial
inhibition of VEGF achieved by inducible gene targeting
resulted in increased mortality, stunted body growth and
impaired organ development, most notably of the liver.
Administration of mFlt(1-3)-IgG, which achieves a higher
degree of VEGF inhibition, resulted in nearly complete
growth arrest and lethality. Ultrastructural analysis
documented alterations in endothelial and other cell types.
Histological and biochemical changes consistent with liver
and renal failure were observed. Endothelial cells isolated
from the liver of mFlt(1-3)-IgG-treated neonates
demonstrated an increased apoptotic index, indicating that
VEGF is required not only for proliferation but also for
survival of endothelial cells. However, such treatment
resulted in less significant alterations as the animal
matured, and the dependence on VEGF was eventually lost
some time after the fourth postnatal week. Administration
of mFlt(1-3)-IgG to juvenile mice failed to induce apoptosis
in liver endothelial cells. Thus, VEGF is essential for
growth and survival in early postnatal life. However, in the
fully developed animal, VEGF is likely to be involved
primarily in active angiogenesis processes such as corpus
luteum development.
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found so far for immature retinal vessels (Alon et al., 1995;
Benjamin et al., 1998), or tumor-associated microvessels
(Borgström et al., 1998; Yuan et al., 1996).
To address the role of VEGF in postnatal development, we
sought to inactivate this factor by two independent approaches:
Cre-loxP-mediated gene ablation after administration of
interferon-a or of a soluble VEGF receptor chimeric protein,
mFlt(1-3)-IgG. Our results demonstrate that VEGF is not only
a critical regulator of organ and body size but, unexpectedly,
that it is also essential for survival in early postnatal life.
MATERIALS AND METHODS
Construction of targeting vector and introduction in ES
cells
A 18-kb genomic VEGF genomic clone encompassing exons 1 to 4 of
the murine VEGF locus (Ferrara et al., 1996) was used to generate a 1.9
kb BamHI-XbaI fragment encoding exon 2 of VEGF, which was blunt
end cloned into the NotI site of TNLOX1-3 targeting vector. A 1.6 kb
XbaI-EcoRI fragment, encoding exon 3, was blunt end cloned into the
AscI site and a 3.4 kb EcoRI-KpnI fragment, including exon 4, was blunt
end cloned into the PmeI site. All loxP-sites of the targeting vector
TNBCE were sequenced and the orientation of the inserts verified by
restriction digestion and sequencing. The targeting vector was linearized
by SalI digestion and 20 m g were used for electroporation of the ESGS
clone derived from 129Sv ES cells. Characterization of this ES cell line
and tissue culture conditions have been described previously (Huang et
al., 1993). Briefly, cells were cultured on mouse embryonic fibroblast
layer in the presence of 1000 i.u./ml of murine LIF (Gibco) in high
glucose DMEM (Gibco) supplemented with 10% fetal bovine serum
(FBS). Cells were subjected to G418 selection (400 m g/ml) and single
colonies were analyzed for positive recombination events by Southern
blot. The probe was generated by random prime labeling of a 1.8 kb
BamHI fragment derived from the 5¢ upstream region of the VEGF locus.
The genomic DNA was digested with KpnI and SacII and positive clones
were identified by generation of a new 12 kb fragment in addition to the
10 kb wild-type allele. Positive recombination events were observed at
a frequency of 1:100. Subsequently, colonies were analyzed for complete
recombination of the 3¢ region, including the loxP-3 site, by PCR
analysis using oligonucleotides VEGFc5R.2 (ACA TCT GCT GTG
CTG TAG GAA G) and VEGFe3.F (GAC CTG AAT TCG CGC CAT
AAC T). Three independent ESGS clones were selected and transiently
transfected with an expression vector encoding CRE recombinase
(pMC-Cre) fused to the nuclear location signal of SV40 large T-antigen.
100 colonies were selected randomly and analyzed by PCR and Southern
blot analysis for loss of the PGK-NEO gene and the flanking loxP-site.
This was monitored by reduction of the PCR fragment from 2.5 kb to
0.9 kb applying the loxP-specific oligonucleotide VEGFb3lox.F (TCT
AGG GCC GCC TCG AGA TAA C) and VEGFex.R (CAT CGT TAC
AGC AGC CTG CAC A). The latter oligonucleotide was designed to
hybridize to exon 3 of the mouse VEGF gene. The presence of the loxP-
3 sequence was verified using oligonucleotides VEGFc5R.2 and
VEGFe3.F. Selected ES colonies were grown to confluency and VEGF
levels in the supernatant were determined by a radioreceptor assay using
Flk-1/KDR-IgG (Presta et al., 1997). The genomic DNA isolated from
these clones was digested with EcoRI and analyzed by Southern blotting
using the random primed 1.8 kb BamHI 5¢ probe described above.
Generation of VEGF/loxP mice
One derivative of each ES cell line containing the floxed VEGF allele
was injected into the blastocoele cavity of 3.5-day C57BL/6J
blastocysts (Hogan et al., 1994). Chimeric males were mated with
C57BL/6J females and agouti offsprings were screened for germline
transmission by PCR analysis for VEGF alleles containing the loxP-
1 and loxP-3 sites. Heterozygous VEGF- loxP - males were bred to
MX-1-Cre mice to generate VEGF- loxP - (+/- ), MX-1-Cre(+) mice
and these were bred by brother-sister mating to VEGF- loxP - (+/+),
MX-1-Cre(+) mice. Mice were bred to homozygosity based on PCR
analysis of tail DNA using primer pairs muVEGF419.F (CCT GGC
CCT CAA GTA CAC CTT) and muVEGF567.R (TCC GTA CGA
CGC ATT TCT AG), which generate a 148 bp fragment of the VEGF
allele in the presence of the loxP-1 site, and a shorter fragment of
about 40 bp for the wild-type allele. The presence of the MX-1 Cre
transgene was verified by tail DNA PCR using the oligonucleotides
CRE1 (CCT GTT ACG TAT AGC CGA AAT) and CRE2 (CTA CAC
CAG AGA CGG AAA TC).
VEGF gene ablation by IFN- a administration
10000 units of recombinant murine IFN-a (Chemicon) were
administered intraperitoneally to newborn mice at days 3, 5 and 7. 12-
15 days after beginning of treatment, mice were killed and tissues were
fixed for histological analyses or frozen in liquid nitrogen for
determination of genotype and knock out efficiency in various tissues.
DNA was prepared using the genomic DNA isolation kit from Qiagen.
Knock out efficiency was assessed by ‘real time’ quantitative PCR
(TAQMAN) (Gibson et al., 1996; Heid et al., 1996) of genomic DNA
isolated using probe/primer sets recognizing the ‘floxed’ VEGF alleles
at the loxP-1 or the loxP-3 site. For determination of recombination
efficiency at the loxP-3 site, VEGFc5Probe2 and primers VEGFc5R.2
and VEGFe3.F were used, and at the loxP-1 site, mVEGF 359.FP
5¢ (FAM)-TGG CAG GCT GAG CCA CCA TTT G-(TAMRA)p3¢ and
primers mVEGF322.F (ACT TCA TGG ACA GGC TTC GG) and
mVEGFloxP-1.552.R (CTA GCG CGC CAT AAC TTC G) for loxP-1.
Treatment of mice with mFlt(1-3)-IgG
C57BL-6 newborn mice were injected intraperitoneally once daily
starting at day 1 or day 8 post delivery with 25 mg/kg/day of mFlt(1-
3)-IgG in PBS in a total volume of 50 m l per dose. mFlt(1-3)-IgG is
a fusion protein consisting of the first three Ig-like domains of mFlt-
1 fused to a murine Fc ( g 2B) (Ferrara et al., 1998). Previous studies
have shown that this truncated soluble receptor has the same binding
characteristics as Flt(1-7)-IgG, but its half-life following systemic
administration is substantially longer (Davis-Smyth et al., 1996).
mFlt(1-3)-IgG was purified and characterized as previously described
(Ferrara et al., 1998). Controls were a murine anti-gp120 monoclonal
antibody of same IgG isotype as the Fc in mFlt(1-3)-IgG,
administered at the same dose, or PBS. Body mass measurements
were taken daily. After treatment, animals were killed by
pentobarbital administration and the tissues were harvested and fixed.
Capillary counts
All tissues for immunohistochemistry were formalin-fixed and
paraffin-embedded. For capillary counts, immunohistochemistry was
performed on kidney, liver, heart and lung sections from animals
treated with control IgG or mFlt(1-3)-IgG. After a 20 minute exposure
to AR10 (Biogenex) at 96°C, sections were incubated with a rat anti-
murine Flk-1 monoclonal antibody at 3.9 m g/ml overnight at 4°C. This
antibody (MALK-1), raised against recombinant mouse Flk-1(1-7)-
IgG fusion protein, belongs to the IgG2A isotype. MALK-1 stains
primarily non-arterial vascular endothelium. In contrast, an anti-CD31
antibody (Pharmingen) labels all vascular endothelial cells. Although
changes in blood vessel density appeared qualitatively similar using
both antibodies, MALK-1 gave a lower background and more
consistent staining than anti-CD31. Therefore, data obtained with
MALK-1 will be shown. A biotinylated rabbit antibody to rat IgG
(Vector) was used as the secondary reagent and detected by the
DuPont Tyramide Signal Amplification Kit (NEN Life Science
Products). Purified rat IgG2A was used as a negative control. To
quantitate blood vessel density, Flk-1-immunostained sections were
examined through a 10· 10 eyepiece grid under a 40· objective. At
this magnification, the grid covered an area of 0.063 mm2 (25 m m ·
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25 m m). Random regions were selected such that the grid was filled
with the parenchyma of each tissue. Each square within the grid that
did not contain a Flk-1-positive endothelial cell was scored. The
minimum possible score is 0 and the maximum score 500, where 500
would indicate a complete absence of Flk-1-positive cells. Five
independent, randomly selected fields were counted from each organ
of three animals. Data are shown as means ± s.d.
Cell proliferation analysis
Immunohistochemistry was performed on sections of BrdU-
incorporated kidney, heart, liver and lung from control IgG or mFlt(1-
3)-IgG-treated animals. BrdU was administered intraperitoneally to
animals at a dose of 100 mg/kg, 1 hour prior to killing. After a 20-
minute treatment with 0.05% trypsin at 37°C and a 45-minute
treatment with 95% formamide in 0.15 M trisodium citrate at 70°C
for denaturing, tissues were stained with mouse anti-IdU/BrdU
(Caltag) at a dilution of 1:1000 overnight at 4°C. A biotinylated horse
anti-mouse IgG (Vector) was used as the secondary reagent and
detected by using the Vectastain ABC Standard Elite kit (Vector
Laboratories). Mouse Isotype (Zymed) was used as a negative control.
Sections were counterstained with Hematoxylin and labeled nuclei in
ten independent, randomly selected, fields using a 40 · objective were
counted. Each field covered an area of 0.063 mm2.
Electron microscopy
Tissues from control IgG and mFlt(1-3)-IgG treated animals were
fixed for 2 hours in 2% formaldehyde, 2.5% glutaraldehyde in 0.1 M
cacodylate buffer. After washing, the samples were postfixed in
aqueous 1% osmium for 2 hours, washed in water, dehydrated through
graded ethanols and propylene oxide, and embedded in EPONATE 12
(Ted Pella, Inc. Redding, Ca). Ultrathin sections were cut on a
Reichert Ultracut E microtome, counterstained with uranyl acetate
and lead citrate, examined in a Philips CM12 transmission electron
microscope at 80 kV and images were captured with a GATAN
Retractable Multiscan digital camera.
Isolation of liver endothelial cells and apoptosis analysis
Mice that had been treated for 3 days with mFlt(1-3)-IgG or control
IgG were perfused with 10 ml of 1 mg/ml collagenase, 10 mg/ml, 10%
FBS in Opti-MEM (Gibco) for 5 minutes. Livers were harvested and
transferred to 10 ml of collagenase digestion buffer (Opti-MEM
complemented with BSA (10 mg/ml, Bayer), 10% FBS (Gibco) and
collagenase H (1 mg/ml). After mechanically dispersing the tissues
into 1 mm3 cubes, fragments were digested at 37°C for 30 minutes in
10 ml of collagenase digestion buffer. The resulting suspension was
filtered through a Falcon 2350 restrainer cap (70 m m cut-off
membrane). Cells were centrifuged for 5 minutes at 1000 rpm, and
resuspended in Opti-MEM complemented with BSA (10 mg/ml) and
10% FBS. This washing procedure was repeated twice. Cells were
resuspended in 1 ml of binding buffer (Opti-MEM, 10 mg/ml BSA,
10% FBS, 0.05% sodium azide) and incubated on ice with IgG2A rat
anti mouse CD31-FITC (MEK 13.3, Pharmingen) at 5 m g/ml for about
30 minutes. Alternatively, cells were incubated with a biotin-
conjugated anti-mouse Panendothelial Cell Antigen (5 m g/ml, MECA
32, Pharmingen) and 10 m l of FITC-conjugated avidin (Pharmingen).
Cells were washed twice in Ca-binding buffer (10 mM Hepes/NaOH,
pH 7.4, 140 mM NaCl, 2.5 mM CaCl2). For apoptosis analysis, cells
were immediately afterwards incubated with 10 m l of annexin-V-PE
(R&D systems) in a total volume of 1 ml Ca-binding buffer for 15
minutes on ice prior to FACS analysis. The control PE-labeled
antibody was IgG2A-PE (Becton Dickinson). Cells negative for both
propidium iodide (PI) staining and annexin V binding, but CD31-
positive, were considered to be live endothelial cells. PI-negative,
annexin V- and CD31-positive cells were considered early apoptotic
endothelial cells; PI-positive, annexin V- and CD31-positive cells are
primarily cells in late stage of apoptosis (Moore et al., 1998).
RESULTS
Impaired growth following conditional VEGF gene
inactivation
To elucidate the significance of VEGF in postnatal development,
we applied the Cre-loxP-based conditional gene knock-out
technology (Gu et al., 1994). A targeting vector was generated
in which exon 3 of the mouse VEGF gene is flanked by 
loxP sites (Fig. 1A). We obtained VEGFloxP(+/- ) and
VEGFloxP(+/+) mice at the expected Mendelian ratio (data not
shown). Analysis of VEGF release by ES cells revealed that
Fig. 1. Generation of conditional VEGF
knock out mice. (A) Structure of the
targeting vector. loxP sites were placed at
the XbaI and EcoRI sites, respectively,
flanking exon 3. (B) Southern blot analysis
of ES cell clones containing both wild-type
VEGF alleles (Wt), one wild-type and one
floxed allele (Flox) or one wild-type and
one allele deleted in exon 3 of VEGF (D ),
following transient transfection with Cre
recombinase (pMC-Cre). The upper part of
B indicates the levels of VEGF in the
supernatant of each ES cell colony.
(C) Knock out efficiencies in various organs
after administration of 10,000 i.u. of IFN- a
intraperitoneally at days 3, 5 and 7
postnatally. Data were generated by real-
time PCR analysis using a LOX-3-specific
probe primer set as described. The IL-8
receptor gene was used as reference. DNA
of three 14-day-old VEGFloxP(+/+)Cre+
and three VEGFloxP(+/+)Cre- animals,
which survived the treatment, were
analyzed; values are ±s.d. (D) Comparison of body sizes between two 14-day-old littermates treated with 10,000 i.u. of IFN- a at days 3, 5 and
7. The VEGFloxP(+/+)Cre+ littermate is shown to the left while the VEGFloxP(- /- )Cre+ (wt) mouse is on the right.
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VEGFloxP(+/- ) clones secrete similar levels of VEGF to wild-
type ES cells, unless exon 3 has been deleted (Fig. 1B),
suggesting that the two loxP sites do not interfere with normal
VEGF expression. Mice containing the ‘floxed’ VEGF allele
were bred to a strain transgenic for Cre recombinase controlled
by an interferon (IFN)-a -responsive promoter (MX-1-Cre)
(Kuhn et al., 1995). Intraperitoneal administration of
recombinant mouse IFN-a to VEGF-loxP(+/+)Cre+ neonate
mice resulted in knock out efficiencies in various organs ranging
from 50% in the kidney to 95% in the liver, spleen and bone
marrow (Fig. 1C). The lowest efficiency was detected in the lung
(<30%). These findings probably reflect differences in the
expression of IFN receptors as well as in the bioavailability of
IFN-a in various tissues and organs (Kuhn et al., 1995). As
indicated in Table 1, administration of IFN-a resulted in reduced
body mass gain in VEGFloxP(+/+)Cre+ animals, while their
VEGFloxP(+/+)Cre- littermates grew at normal rates (Table 1).
Furthermore, 38% of VEGF loxP(+/+)Cre+ animals treated
died around day 7. Interestingly, a trend toward reduced body
growth was also observed in VEGFloxP(+/- )Cre+ mice
following IFN-a administration, suggesting a dosage effect.
However, IFN-a administration to 6- to 10-week-old
VEGFloxP(+/+)Cre+ mice did not induce any significant
changes in body or organ mass relative to age-matched
VEGFloxP(+/+)Cre- mice.
Abnormal liver development in VEGF knockout mice
Consistent histological changes were observed in livers of 14-
day-old VEGFloxP(+/+)Cre+ mice, treated with IFN- a (Fig.
2A,B). Hepatocytes were small and rounded and the hepatic
sinusoidal architecture remained immature, with persistence
of twin cell hepatic plates. In addition, many sinusoids
contained prominent eosinophilic histiocytes. There was
increased extramedullary hematopoiesis and almost complete
absence of Flk-1-positive endothelial cells (Fig. 3C,D). The
heart, kidney, lung and spleen were all within normal
histological limits, albeit small in size. The more profound
liver phenotype is consistent with the high knock out
efficiency in this organ.
Inhibition of organ development and lethality in
neonatal mice treated with mFlt(1-3)-IgG
To verify these findings by an independent approach, we used
a truncated soluble Flt-1 receptor, mFlt(1-3)-IgG (Ferrara et al.,
1998). Systemic administration of mFlt(1-3)-IgG resulted in
almost complete inhibition of VEGF-induced angiogenesis in
a rat model of hormonally induced ovulation (Ferrara et al.,
1998). Initiation of treatment in neonatal mice either at day 1
or 8 postnatally resulted in reduced mass gain (Fig. 4A,C),
more pronounced than that observed with Cre/loxP- mediated
gene targeting. As little as 1 mg/kg of mFlt(1-3)-IgG
administered daily resulted in a detectable inhibition compared
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Table 1. Analysis of growth retardation and mortality of
newborn mice of different genotype
% Growth % Animals with
% Mortality retarded normal body
Genotype at day 7 survivors* mass at day 27
VEGF loxP(+/+)
Cre+ (n=21) 38 52 10
VEGF loxP(+/- )
Cre+  (n=6) 0 33 66
VEGF loxP(+/+)
Cre- (n=10) 0 0 100
All groups were treated with 10,000 i.u. of IFN-a at days 3, 5 and 7
postnatally.
*Values >20% compared to control littermates were counted.
Table 2. Blood chemistry and hematology parameters following mFlt (1-3)-IgG or control IgG administration
Time after Glu BUN Alb Total protein K+
treatment (mg/dl) (mg/dl) (g/dl) (g/dl) (meq/l)
(A) Day 5
Control IgG (n=14) 68±4 31±1 0.52±0.06 2.43±0.05 7.4±0.6
Flt (1-3)-IgG (n=11) 32±8* 45±6* 0.53±0.09 2.52±0.15 8.0±0.5
Day 14
Control IgG (n=10) 89.7±3.5 25±1 1.3±0.2 3.1±0.1 8.6±0.6
Flt (1-3)-IgG (n=9) 57.1±9.3* 204±18* 0.7±0.3* 2.2±0.3* 13.1±1.2
WBC RBC HGB HCT PLT
(103/m l) (106/m l) (g/dl) (%) (103/ m l)
(B) Day 5
Control IgG (n=6) 7.9±1.1 3.4±0.1 10.2±0.3 27.4±0.9 521±13
Flt (1-3)-IgG (n=8) 12.3±1.0* 4.5±0.1 13.1±0.5 33.9±1.2 349± 46**
Day 14
Control IgG (n=15) 4.6±0.4 5.3±0.1 9.9± 0.2 27.6±0.3 906±35
Flt (1-3)-IgG (n=9) 20.3±3.3* 5.3±0.3 11.7±0.6* 32.3±1.6* 520±50**
.
(A) Glucose (Glu), blood urea nitrogen (BUN), albumin (Alb) total protein (Pr) and potassium (K+)) levels in the serum  of animal treated with control IgG or
mFlt(1-3)-IgG. Blood was collected at the time of killing.
In the day-5 groups, the treatment was initiated at day 1 and daily injections were given for 4 days.
In the day-14 groups, the treatment was initiated at day 8 and continued by daily injections.
The dose of both IgGs was 25 mg/kg daily. Values are means ± s.e.m. Values are significantly different, *P<0.05; **P<0.005.
(B) Hematological parameters of the above described groups. WBC, white blood cells; RBC, red  blood cells; HGB, hemoglobin; HCT, hematocrit; PLT,
platelets.
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to PBS- or mIgG-treated animals (data not shown). A
maximum inhibitory effect was observed at the dose of 25
mg/kg daily. All animals treated with such a dose died within
4-6 days. The difference in mass gain and survival between
mFlt(1-3)-IgG treated and Cre/loxP-animals may be explained
by the partial VEGF inhibition achieved by the inducible
targeting system, in contrast to the nearly complete inhibition
with mFlt(1-3)-IgG (Ferrara et al., 1998). In view of the more
profound phenotype obtained, most analyses were performed
on mFlt(1-3)-IgG-treated animals.
At necropsy, all animals given mFlt(1-3)-IgG starting at day
1 or 8, were smaller than controls (Fig. 4A,B) and all major
organs were reduced in size (Fig. 4C,D). However, similar
amounts of milk were found in the stomach of control and
mFlt(1-3)-IgG-treated groups, indicating that inadequate
feeding is unlikely to be the cause of impaired growth. The
most dramatic change in gross organ size were observed in the
kidney (Fig. 4E), heart (Fig. 4F) and liver. The kidneys were
shrunken, had a granular surface and showed focal interstitial
hemorrhage.
Histopathogical analysis (Ribelin and Cox, 1965) revealed
differences between the day-5 and day-14 groups. In day-5
animals, there was a striking reduction in brown fat stores,
and some had thymic involution, suggesting severe metabolic
stress. Some large vessels had focal adherence of leukocytes
to the endothelium, and in some there was leukocytoclastic
vasculitis (Fig. 2D), indicating vascular injury. No evidence
of vasculitis was found in animals treated with control IgG.
The kidneys showed interstitial hemorrhage at the
corticomedullary junction (Fig. 4E). Juxtamedullary and
cortical glomeruli were enlarged, hypocellular and showed
accumulation of eosinophillic mesangial matrix. Glomerular
capillary loop numbers were reduced compared to controls
and proximal tubular epithelium contained protein droplets
(data not shown). Ultrastuctural analysis of kidneys of treated
animals showed that glomerular capillaries were
underdeveloped and in some instances entirely missing.
Interestingly, these alterations appeared to be mostly
restricted to juxtamedullary glomeruli. There was an
increased mesangial matrix (Fig. 5B,D) with granular
material and proteinaceous deposits that included fibrin but
no immune complexes were detected. The cytoplasmic foot
processes of podocytes were normal in appearance and
interacted with a thickened basement membrane.
Interestingly, the capillaries in the peritubular regions showed
normal fenestration in about half the profiles surveyed (Fig.
5F). Kidneys from animals given control IgG appeared
normal (Fig. 5A,C,E).
In the liver, portal tracts were small and hypercellular and
the sinusoidal architecture showed persistence of the fetal
vascular pattern (Ribelin and Cox, 1965). Ultrastructural
analysis showed that livers of the treated animals had reduced
numbers of endothelial cells and focal loss of integrity of the
space of Disse (Fig. 6B). When the endothelial cells were
absent, hematopoietic cells could be often seen in direct
contact with the hepatocyte plasma membrane. Bile canaliculi
displayed normal morphology. The controls showed normal
morphology (Fig. 6A).
In the heart, single cell necrosis of cardiomyocytes was
observed (Fig. 2C) and the lungs from treated animals appeared
immature, with less complex alveolar patterning (Fig. 2G,H).
Spotty single cell necrosis was also observed in the liver,
pancreas and spinal ganglia (data not shown).
In the day-14 group, a striking glomerulopathy, affecting
all glomeruli, was observed (Fig. 2E,F). Glomeruli were
uniformly enlarged and hypocellular, and mesangial cells
showed cytoplasmic vacuolation. In the liver of mFlt(1-3)-
IgG-treated animals, microvesicular steatosis was present
and occasional apoptotic cells were observed within the
hepatic parenchyma. In Fig. 6, the depletion cells lining the
sinusoids in the treated group is evident. At this stage, heart,
lung, intestine and pancreas all appeared histologically
normal. Interestingly, in contrast to the day-5 treatment
group, there was only a modest decrease in the adipose tissue
content in the day-14 group following mFlt(1-3)-IgG
treatment.
Table 3. Blood vessel absence determination in liver, heart
and kidney and measurement of cell proliferation by BrdU
labeling in liver, heart, lung and kidney of animals treated
with control IgG or mFlt (1-3)-IgG
Blood vessel quantification by Flk-1-positive cells
Liver Heart Kidney
Day 5
Control IgG 7.3±2.5 2.7±2.1 124.3±11.6
Flt (1-3)-IgG 83.3±15.6 61.7±12.7 175.3±12.3
Day 14
Control IgG 3.3±1.5 4.7±1.5 NA
Flt (1-3)-IgG 231.5±77.1 94.5±29.0 NA
Cell proliferation (BrdU labeling)
Liver Heart Lung Kidney
Day 5
Control IgG 580.6±58 349.3±52.1 160.3±32.7 295.6±52.7
Flt (1-3)-IgG 298±74.1 37±20.5 13.0±2.7 105±33.7
The minimum possible score for the absence of blood vessels is 0, and the
maximum score 500, where 500 would indicate a complete absence of Flk-1
positive cells.
In the day-5 groups, the treatment was initiated at day 1 and daily
injections were given for 4 days.
In the day-14 groups, the treatment was initiated at day 8 and continued by
daily injections.
Table 4. Apoptosis in endothelial cells after treatment with
mFlt (1-3)-IgG or control IgG
CD31 positive Apoptotic, CD31 positive
Day 11
Control IgG (n=3) 18.9±1.9 2.1±0.4
Flt(1-3)-IgG (n=3) 4.1±0.3* 14.3±2.1*
Day 27
Control IgG (n=4) 16.3±3.1 4.0±0.4
Flt(1-3)-IgG (n=4) 15.2±2.1 4.0±1.2
In the day-11 group, animals were treated for 3 days with control IgG or
mFlt (1-3)-IgG, starting at day 8 postnatally.
In the day-27 group, the same treatment was initiated at day 24.
The dose of both IgGs was 25 mg/kg daily.
Isolation of endothelial cells and apoptosis assessment by FACS were
performed as described in Materials and methods.
Values are % of total and are means±s.e.m. *Significantly different P<0.005.
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Administration of mFlt(1-3)-IgG to adult mice for 2 or 4
weeks failed to induce any significant changes in body mass
relative to controls. All the major organs were normal by
histological examination (data not shown).
Severe renal failure and tissue hypoxemia in mFlt(1-
3)-IgG-treated neonates
In agreement with the histopathological picture of kidney and
liver damage, the levels for blood urea nitrate (BUN) were
increased, especially in the group where mFlt(1-3)-IgG
treatment was initiated at day 8 (Table 2). Decreased levels
of albumin and total proteins are also consistent with this
picture (West, 1990). Also, consistent with kidney failure,
mFlt(1-3)-IgG-treated animals in the day 8-group
demonstrated critically elevated serum K+ levels (Table 2), a
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Fig. 2. PAS stained images from the perivenular (V) region of the
liver from control (A) and VEGFloxP(+/+)Cre+ mice treated with
IFN-a (B). The hepatocytes in VEGF knock out animals were
smaller, more densely packed and the sinusoidal architecture had
failed to mature into the normal adult pattern of single cell
hepatocyte plates. Frequent PAS-positive cells were seen within
hepatic sinusoids, and the cells have the morphological features of
macrophages (arrow) of KO mice. (C) Hematoxylin and eosin
staining of the heart of a 5-day-old neonate treated with mFlt(1-3)-
IgG, showing apoptotic myocytes (arrowhead), and of the lumen and
wall of a vein of a 5-day-old neonate treated with mFlt(1-3)-IgG (D),
showing adherence of leukocytes to endothelium, sub-endothelial
leukocyte infiltration (arrowhead) and areas of necrosis in the
vascular wall (arrow). (E,F) Hematoxylin and eosin staining of
glomeruli from 14-day-old animals treated for 5 days with control
antibody (E) or mFlt(1-3)-IgG (F). The enlarged, hypocellular
glomeruli contained few capillary loops and were filled with large
vacuolated cells. (G,H) Hematoxylin and eosin staining of lungs
from 5-day-old control (G) or treated (H) animals The lungs from
mFlt(1-3)-IgG-treated animals appeared immature, with less
complex alveolar patterning. B, main bronchus. Bars, 40 m m (C,D);
100 m m (A,B,E,F); 400 m m (G,H).
Fig. 3. BrdU labeling of lung and Flk-1 immunostaining of liver and
heart. (A,B) BrdU labeling of sections of lung of 5-day-old control
IgG (A) or mFlt(1-3)-IgG-treated mice (B). More positively labeled
cells (arrows) were seen in control animals (arrowhead points to
bronchial epithelium). (C,D) Flk-1 immunostaining of livers from
control (C) and mFlt(1-3)-IgG-treated mice (D). Arrowheads point
towards Flk-1 staining in sinusoidal endothelium. Arrows point
toward Flk-1 staining on venular endothelium in a portal tract. P,
portal tract; V, terminal hepatic venule. Bars, 400 m m. (E,F) Flk-1
immunostaining of hearts from 5-day-old mice treated with control
antibody (E) or mFlt(1-3)-IgG (F). Positively labeled vessels are
marked (arrowhead). (G,H) Flk-1 immunostaining of livers of 14-
day-old VEGFloxP(+/+)Cre - (G) and VEGFloxP(+/+)Cre+ (H)
mice, both treated with IFN-a as described in the text. Bars, 40 m m
(A,B); 200 m m (E,F); 400 m m (C,D).
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change expected to predispose to cardiac arrhythmias (West,
1990).
Increases in hematocrit and hemoglobin levels were
observed in animals at both age groups following mFlt(1-3)-
IgG treatment (Table 2). Quantitative PCR analysis (Gibson et
al., 1996) demonstrated a 3- to 6-fold increase in erythropoietin
expression in the kidney (data not shown). These findings are
consistent with a homeostatic response to systemic hypoxemia
(Jelkmann, 1992) resulting from pulmonary and cardiac
hypoplasia. Interestingly, animals treated with mFlt(1-3)-IgG
in both age groups had significantly lower platelet counts than
controls (Table 2).
Reduced proliferation rates and increased apoptotic
index among parenchymal cells correlate with a
reduction in capillary vessels
Immunohistochemistry for the endothelial cell markers CD31
(data not shown) and Flk-1 revealed a reduction in the number
and complexity of capillary vessels in the kidneys, livers and
hearts of mFlt(1-3)-IgG-treated animals (Fig. 3E-H;
Table 3). To quantify cell proliferation in the day-5
animals, BrdU labeling was performed. Proliferation
was reduced in the liver, heart, lung and kidneys of
treated animals (Fig. 3A,B; Table 3).
In situ hybridization showed that VEGF and Flk-
1 mRNAs were widely expressed, in agreement with
previous studies (Monacci et al., 1993; Quinn et al.,
1993). Flk-1 showed expression on endothelial cells
in a distribution which, for the most part,
complemented that observed with VEGF. The major
change observed in mFlt(1-3)-IgG animals was a
reduction in Flk-1 mRNA expression in the lung,
similar to that observed by immunohistochemistry
(data not shown). To determine whether apoptosis
contributed to the observed impairment in body
growth, we performed apoptag labeling. Increased
apoptosis was significant in lymphoid cells of the
thymus and hearts of day-5 group (Fig. 2C).
Age-dependent endothelial cell apoptosis
following VEGF inhibition
To determine directly whether decreased levels of
VEGF may result in increased endothelial cell
apoptosis, we established a procedure for the rapid
isolation of liver endothelial cells and subsequent
analysis by FACS. We isolated endothelial cells from
the livers of 11- or 27-day-old mice that had been
treated for 3 days with control IgG or mFlt(1-3)-IgG.
This treatment schedule was not associated with
neonatal mortality. We then determined the ratios of
apoptotic endothelial cells by using an antibody
directed against anti-CD31, which is expressed on
the surface of endothelial cells (Vecchi et al., 1994),
combined with annexin-V binding (Moore et al.,
1998). As shown in Table 4, 18.9% of endothelial
cells isolated from the liver of control animals were
CD31 positive and 2.1% of these were positive for
annexin-V. The ratio increased to 14.3% apoptotic,
CD31-positive cells in mice treated with mFlt-IgG.
At the same time, the level of CD31-positive
endothelial cells dropped to 4.1% of the total cells
isolated. Similar findings were obtained when we applied
another, pan-endothelial cell marker, MECA 32 in the FACS
analysis (data not shown). However, 27-day-old mice showed
no significant changes in the numbers of CD31-positive cells
nor in the ratios of annexin-V binding.
DISCUSSION
We adopted two independent approaches to inactive VEGF:
conditional, Cre-loxP-mediated, VEGF- gene ablation, which
achieves partial gene inactivation, and the administration of a
soluble VEGF receptor chimeric protein, mFlt(1-3)-IgG, which
results in a high degree of VEGF neutralization. Partial VEGF
inactivation leads to impaired body growth and increased
mortality. More profound inhibition results not only in nearly
complete inhibition of somatic growth but also in abnormalities
in a variety of organs, leading to rapidly lethal metabolic
failure. Our findings indicate that VEGF-mediated
Fig. 4. Effect of mFlt(1-3)-IgG on body and organ mass. (A) Growth curve of
mice treated with a control antibody (squares), PBS (circles) or mFlt(1-3)-IgG
(triangles), starting at day 1 postnatally. Values are means ± s.d. (B) Growth curve
of mice treated for 5 days with control IgG (n=10) (squares) or mFlt(1-3)-IgG
(n=10) (triangles) starting at day 8. (C) Organ masses of 5-day-old mice, treated
with control IgG (n=10), shown as tinted columns or mFlt(1-3)-IgG (n=10) for 4
days, shown in black. (D) Organ masses of 14-day-old mice treated for 5 days,
starting at day 8, with control IgG (n=9), shown as tinted columns or mFlt-IgG
(n=6), black columns. (E) Kidneys from 5-day-old neonate mice treated for 4
days. Kidneys from mFlt(1-3)-IgG-treated animals were smaller, had a granular
surface appearance and showed punctuate areas of hemorrhage. The corresponding
histological image shows interstitial hemorrhage at the corticomedullary junction
(arrowhead). (F) Hearts from control and mFlt(1-3)-IgG-treated animals: hearts
from mFlt(1-3)-IgG-treated animals were significantly smaller.
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angiogenesis is a critical rate-limiting step in determining
organ and body size. These findings are partially in contrast
with a previous study, which examined the effects of an anti-
VEGF polyclonal antiserum on newborn mice (Kitamoto et al.,
1997). In agreement with our findings, the treatment resulted
in inhibition of glomerular development. However, it did not
affect body growth or survival nor did it induce lesions in
organs other than kidney. This discrepancy probably reflects
the lower inhibitory activity of the antiserum employed in that
study relative to mFlt(1-3)-IgG.
Interestingly, the post-natal phenotype observed by us is
unlike that observed following inactivation of a major growth
regulatory molecule such as IGF-1. IGF-1- / - mice tend to die
in utero, but those that survive after birth usually reach
adulthood, in spite of a dramatically reduced body size (Baker
et al., 1993). Therefore, impaired organ growth is not sufficient
to account for the lethality observed in the present study and
suggest additional mechanisms.
Although our studies do not directly address the actual
kinetics of cell division and cell
death, they suggest that a major
reason for reduced body growth
in VEGFloxP(+/+) and mFlt(1-
3)-IgG-treated animals is
reduced cell proliferation in all
tissues analyzed. There was
additional evidence of cell loss
through increased levels of
apoptosis of parenchymal cells
within the heart, liver, pancreas
and spinal ganglia of treated
mice (Fig. 2C,G,H and data not
shown), although the overall
ratio did not exceed 1-3%. It
should be noted that apoptosis
(measured by TUNEL) is a
more rapid process than the
time taken to complete the S-
phase of the cell cycle
(measured by BrdU labeling).
Therefore, we cannot rule out
the possibility that slightly
increased levels of apoptosis in
the different tissues may
represent a significant number
when the numbers are
compensated for the small time
window of detection, as
suggested by tumor inhibition
studies (O’Reilly et al., 1997).
There is evidence that VEGF
inhibits endothelial cell
apoptosis in vitro (Gerber et al.,
1998a,b) and it may function in
vivo as a survival factor, at least
for immature retinal vessels
(Alon et al., 1995) and tumor
vessels (Yuan et al., 1996).
However, in contrast to
parenchymal cells, we were
unable to detect consistent
differences in the levels of apoptotic endothelial cells in
mFlt(1-3)-IgG-treated animals and in conditional knock out
mice by applying the TUNEL staining technique (data not
shown). This may be due, at least in part, to the fact that
endothelial cells undergoing apoptosis tend to rapidly lose their
attachment to the basement membrane (Augustin et al., 1995;
Benjamin and Keshet, 1997). In addition, apoptotic endothelial
cells may become the target of the immune system and thus
are eliminated by phagocytes as soon as they manifest early
signs of apoptosis. To overcome these limitations, we decided
to employ a novel approach to assess endothelial cell apoptosis.
We quantified apoptosis in endothelial cells freshly isolated
from the liver of animals treated with mFlt(1-3)-IgG or control
IgG. Such analysis revealed not only fewer endothelial cells
overall but also a significant increase in the percentage of
apoptotic endothelial cells, when the isolation was performed
from mFlt(1-3)-IgG-treated neonates. Such findings
demonstrate that endothelial cells undergo apoptotic cell death
in response to VEGF inactivation. These findings are in
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Fig. 5. Electron micrograph of glomeruli from control IgG (A,C,E) and mFlt(1-3)-IgG-treated (B,D,F)
4-day-old neonates. Severe mesangiolysis with loss of capillary architecture and disintegration of
endothelial cells, accumulation of material (*), fibrils and thickening of the basement membrane (BM)
can be seen in the mFlt(1-3)-IgG-treated animals. Processes of the podocytes (p) are in contact with the
basement membrane. Arrows point to fenestrations in endothelial cells (E,F). Control kidneys
displayed normal morphology (A,C,E). Bars, 1 m m.
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agreement with the dramatic loss of Flk-1-positive cells and
with the marked decrease in endothelial cells lining the
vascular bed in liver and kidney, as assessed by ultrastructural
analysis. Thus, apoptotic cell death may be a major contributor
to the decrease in capillary vessels found in most organs after
VEGF inactivation and eventually resulting in lethality.
VEGF has been associated with the development of
fenestrations in endothelial cells (Roberts and Palade, 1995;
Esser et al., 1998). In agreement with this hypothesis, we
observed a reduction in the number of fenestrations in
glomerular endothelial cells following mFlt(1-3)-IgG
administrations. However, approximately half of the profiles
examined demonstrated fenestrations, suggesting that factors
other than VEGF are important in this process.
Considerable evidence indicates that VEGF plays a
regulatory role in early hematopoiesis and implicates Flk-
1/KDR in mediating such effects (Broxmeyer et al., 1995;
Shalaby et al., 1995, 1997). Hematopoietic stem cells,
megakaryocytes and platelets normally express this receptor
(Katoh et al., 1995). Consistent with this hypothesis, we
detected a decrease in platelet numbers following mFlt(1-
3)-IgG administration. In contrast, the erythrocyte count
did not fall below normal. This may be explained by a
superimposed compensatory response to hypoxia,
mediated by Epo (Jelkmann, 1992).
Although the emphasis of our study is on the role of
VEGF in early postnatal development, it is important to
stress that the dependence on VEGF is eventually lost
when the animal matures and reaches adulthood.
Treatment with mFlt-(1-3)-IgG failed to increase
apoptosis in endothelial cells isolated from the liver of
27-day-old animals. Consistent with these findings,
administration of mFlt(1-3)-IgG, starting at day 24, for
up to 4 weeks, inhibited angiogenesis in areas of active
proliferation but failed to induce mortality or any
marked changes in blood chemistry, although it was
associated with modest liver and glomerular changes
(data not shown). A similar treatment failed to induce
any significant histopathological abnormality in fully
adult mice. Therefore, a process of maturation occurs,
such that VEGF eventually is no longer essential for
survival. This ‘switch’ seems to happen some time after
the fourth postnatal week and, in the fully adult animal,
VEGF may be required primarily for active angiogenic
processes such as corpus luteum development or wound
healing. The molecular and cellular nature of this
switch remains elusive. Based on studies on the
development of the retinal vasculature, it has been
proposed that pericyte coverage may be the critical
event that determines whether or not endothelial cells
will be dependent on VEGF (Benjamin et al., 1998).
However, our findings suggest that this is unlikely to be
the only mechanism, since organ failure and lethality
follow VEGF inactivation in the postnatal life, when the
microvascular tree is already covered by pericytes
(Hirschi and D’Amore, 1996).
Recently, several VEGF-related molecules have been
identified, including PlGF, VEGF-B, VEGF-C and
VEGF-D (Carmeliet and Collen, 1998; Enholm et al.,
1998). It is known that PlGF and VEGF-B bind Flt-1 but
not Flk-1/KDR In contrast, VEGF-C and VEGF-D bind
the Flt-4 and Flk-1/KDR receptors. Therefore, it is possible
that mFlt(1-3)-IgG may have interacted with PlGF or VEGF-
B, raising the possibility that inactivation of these factors may
contribute to the phenotype described in this study. However,
considerable evidence indicates that binding to Flt-1 alone does
not result in an effective mitogenic (Keyt et al., 1996) or
antiapoptotic (Gerber et al., 1998b) signal in endothelial cells.
Furthermore, inactivation of the PlGF gene in mice does not in
result in any obvious abnormalities (Carmeliet and Collen,
1998).
In the present set of experiments, we chose a systemic
approach to address the impact of VEGF inactivation in a
whole body context and to assess the toxicity of anti-VEGF
treatment in a rapidly growing organism. The availability of
tissue-specific, conditional, knock out technology in mice may
be instrumental in shedding light into the role of VEGF during
development in specific organs, as well as in adult stages. This
novel technique has the potential to locally delete the VEGF
gene, while providing unimpaired levels of VEGF production
in the rest of the body. For example, deletion of the VEGF gene
Fig. 6. Electron micrograph of the livers from control (A) and mFlt(1-3)-IgG
treated (B) 4-day-old neonates. Note the absence of endothelial lining
around a vascular lumen (L) in B. D, space of Disse; e, endothelial cells; H,
hepatocytes. Bars, 1 m m.
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in the embryonic heart or in the ventricles of adult mice may
help in assessing the role of VEGF during heart development
and may also be useful in the development of rational strategies
for therapeutic intervention in ischemic heart disease.
We thank R. Latvala, J. Ross, H. Steinmetz and W. Wong for animal
work, H. Prashad for cell culture, D. Peers for mFlt(1-3)-IgG
purification, G. Meng and G. Hatami for assays, and D. Wood and L.
Tamayo for graphics. We thank the Pathology laboratory and T.-N.
Nguyen for in situ hybridization. We also thank S. Pitts-Meek, M.
Bauer and M. Dowd for microinjections and M. Chu for genotype
analysis. We are indebted to the oligonucleotide synthesis and DNA
sequencing groups. We thank M. Gerritsen and D. Lowe for helpful
discussions and advice.
REFERENCES
Alon, T., Hemo, I., Itin, A., Pe’er, J., Stone, J. and Keshet, E. (1995).
Vascular endothelial growth factor acts as a survival factor for newly formed
retinal vessels and has implications for retinopathy of prematurity. Nat. Med.
1, 1024-028.
Augustin, H. G., Braun, K., Telemenakis, I., Modlich, U. and Kuhn, W.
(1995). Ovarian angiogenesis. Phenotypic characterization of endothelial
cells in a physiological model of blood vessel growth and regression. Am.
J. Pathol. 147, 339-351.
Baker, J., Liu, J. P., Robertson, E. J. and Efstratiadis, A. (1993). Role of
insulin-like growth factors in embryonic and postnatal growth. Cell 75, 73-
82.
Benjamin, L., Hemo, I. and Keshet, E. (1998). A plasticity window for blood
vessel remodelling is defined by pericyte coverage of the preformed
endothelial network and is regulated by PDGF-B and VEGF. Development
125, 1591-1598.
Benjamin, L. E. and Keshet, E. (1997). Conditional switching of vascular
endothelial growth factor (VEGF) expression in tumors: induction of
endothelial cell shedding and regression of hemangioblastoma-like vessels
by VEGF withdrawal Proc. Natl. Acad. Sci. USA 94, 8761-8766.
Borgström, P., Bourdon, M. A., Hillan, K. J., Sriramarao, P. and Ferrara,
N. (1998). Neutralizing anti-vascular endothelial growth factor antibody
completely inhibits angiogenesis and growth of human prostate carcinoma
micro tumors in vivo. Prostate 35, 1-10.
Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T.,
Klier, G. and Cheresh, D. A. (1994). Integrin alpha v beta 3 antagonists
promote tumor regression by inducing apoptosis of angiogenic blood
vessels. Cell 79, 1157-1164.
Broxmwyer, H. E., Cooper, S., Li, Z. H., Song, H. Y., Kwon, B. S., Warren,
R. E., Donner, D. B. (1995). Myeloid progenitor cell regulatory effects of
vascular endothelial growth factor. Int. J. Hematol. 62, 203-215.
Carmeliet, P. and Collen, D. (1998). Vascular development and disorders:
Molecular analysis and pathogenic insights. Kidney Internat. 53, 1519-1549.
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L.,
Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt,
C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W. and Nagy,
A. (1996). Abnormal blood vessel development and lethality in embryos
lacking a single VEGF allele. Nature 380, 435-439.
Clapp, C., Martial, J. A., Guzman, R. C., Rentier-Delrue, F. and Weiner,
R. I. (1993). The 16-kilodalton N-terminal fragment of human prolactin is
a potent inhibitor of angiogenesis. Endocrinology 133, 1292-1299.
Davis-Smyth, T., Chen, H., Park, J., Presta, L. G. and Ferrara, N. (1996).
The second immunoglobulin-like domain of the VEGF tyrosine kinase
receptor Flt-1 determines ligand binding and may initiate a signal
transduction cascade. EMBO J. 15, 4919-4927.
Enholm, B., Jussila, L., Karkkainen, M. and Alitalo, K. (1998).Vascular
endothelial growth factor-C: A growth factor for lymphatic and blood vessel
endothelial cells. Trends Cardiovasc. Med. 8, 292-296
Esser, S., Wolburg, K., Wolburg, H., Breier, G., Kurzchalia, T. and Risau,
W. (1998). Vascular endothelial growth factor induces endothelial
fenestrations in vitro. J. Cell Biol. 140, 947-959.
Ferrara, N., Carver Moore, K., Chen, H., Dowd, M., Lu, L., O’Shea, K.
S., Powell Braxton, L., Hillan, K. J. and Moore, M. W. (1996).
Heterozygous embryonic lethality induced by targeted inactivation of the
VEGF gene. Nature 380, 439-442.
Ferrara, N., Chen, H., Davis-Smyth, T., Gerber, H.-P., Nguyen, T.-N.,
Peers, D., Chisholm, V., Hillan, K. J. and Schwall, R. H. (1998). Vascular
endothelial growth factor is essential for corpus luteum angiogenesis. Nat.
Med. 4, 336-340.
Ferrara, N. and Davis-Smyth, T. (1997). The biology of vascular endothelial
growth factor. Endocr. Rev. 18, 4-25.
Fong, G. H., Rossant, J., Gertsenstein, M. and Breitman, M. L. (1995).
Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of
vascular endothelium. Nature 376, 66-70.
Gerber, H. P., Dixit, V. and Ferrara, N. (1998a). Vascular endothelial growth
factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in
vascular endothelial cells. J. Biol. Chem. 273, 13313-13316.
Gerber, H. P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B., Dixit, V.
and Ferrara, N. (1998b). VEGF regulates endothelial cell survival by the
PI3-kinase/Akt Signal transduction pathway. Requirement for Flk-1/KDR
activation. J. Biol. Chem. 273, 30336- 30345.
Gibson, U. E. M., Heid, C. A. and Williams, P. M. (1996). A novel method
for real time quantitative RT-PCR. Genome Res. 6, 995-1001
Good, D., Polverini, P., Rastinejad, F., Beau, M., Lemons, R., Frazier, W.
and Bouck, N. (1990). A tumor suppressor-dependent inhibitor of
angiogenesis is immunologically and functionally indistinguishable from a
fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 87, 6624-6628.
Gu, H., Marth, J. D., Orban, P. C., Mossmann, H. and Rajewsky, K.
(1994). Deletion of a DNA polymerase beta gene segment in T cells using
cell type-specific gene targeting. Science 265, 103-106.
Hamilton, W. J, Boyd, J. D. and Mossman, H. W. (1962). Human
Embryology. William & Wilkins, Baltimore.
Heid, C. A., Stevens, J., Livak, K. J. and Williams, P. M. (1996). Real time
quantitative PCR. Genome Res. 6, 986-994.
Hiratsuka, S., Minowa, O., Kuno, J., Noda, T. and Shibuya, M. (1998). Flt-
1 lacking the tyrosine kinase domain is sufficient for normal development
and angiogenesis in mice. Proc. Natl. Acad. Sci. USA 95, 9349-9354.
Hirschi, K. K. and D’Amore, P. A. (1996). Pericytes in the microvasculature.
Cardiovasc. Res. 32, 687-698.
Hogan, B., Beddington, R., Costantini, F. and Lacy, E. (1994).
Manipulating the Mouse Embryo, 2nd edition. New York: Cold Spring
Harbor Laboratory Press.
Huang, S., Hendriks, W., Althage, A., Hemmi, S., Bluethmann, H.,
Kamijo, R., Vilcek, J., Zinkernagel, R. M. and Aguet, M. (1993). Immune
response in mice that lack the interferon-gamma receptor. Science 259,
1742-1745.
Jelkmann, W. (1992). Erythropoietin: structure, control of production and
function. Physiol. Rev. 72, 449-489.
Katoh, O., Tauchi, H., Kawaishi, K., Kimura, A. and Sarow, Y. (1995).
Expression of the vascular endothelial growth factor (VEGF) receptor gene,
KDR, in hematopietic cells and inhibitory effects of VEGF on apoptotic cell
death caused by ionizing radiations. Cancer Res. 55, 5687-5692.
Keyt, B. A., Nguyen, H. V., Berleau, L. T., Duarte, C. M., Park, J., Chen,
H. and Ferrara, N. (1996). Identification of vascular endothelial growth
factor determinants for binding KDR and FLT-1 receptors. Generation of
receptor-selective VEGF variants by site-directed mutagenesis. J. Biol.
Chem. 271, 5638-5646.
Kitamoto, Y., Tokunaga, H. and Tomita, K. (1997). Vascular endothelial
growth factor is an essential molecule for mouse kidney development. J.
Clin. Invest. 99, 2351-2357.
Kuhn, R., Schwenk, F., Aguet, M. and Rajewsky, K. (1995). Inducible gene
targeting in mice. Science 269, 1427-1429.
Monacci, W. T., Merrill, M. J. and Oldfield, E. H. (1993). Expression of
vascular permeability factor/vascular endothelial growth factor in normal rat
tissues. Am. J. Physiol. 264, C995-1002.
Moore, A., Donahue, C., Bauer, K. D. and Mather, J. P. (1998).
Simultaneous measurement of cell cycle and apoptotic cell death. In
Methods in Cell Biology (ed. J. P. Mather) ), pp. 266 -278. Academic Press.
Nehls, V. and Drenckhahn, D. (1993). The versatility of microvascular
pericytes: From mesenchyme to smooth muscle? Histochemistry 99, 
1-12.
O’Reilly, M. O., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S.,
Flynn, E., Birkhead, J. R., Olsen, B. R. and Folkman, J. (1997).
Endostatin: An endogenous inhibitor of angiogenesis and tumor growth.
Cell 88, 277-285.
O’Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A.,
Moses, M., Lane, W. S., Cao, Y., Sage, E. H. and Folkman, J. (1994).
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of
metastases by a Lewis lung carcinoma. Cell 79, 315-328.
H.-P. Gerber and others
1159Role of VEGF in neonatal mice
Patan, S., Haenni, B. and Burri, P. H. (1997). Implementation of
intussusceptive microvascular growth in the chicken chorioallantoic
membrane (CAM). Microvasc. Res. 53, 33-52.
Presta, L. G., Chen, H., O’Connor, S. J., Chisholm, V., Meng, Y. G.,
Krummen, L., Winkler, M. and Ferrara, N. (1997). Humanization of an
anti-VEGF monoclonal antibody for the therapy of solid tumors and other
disorders. Cancer Res. 57, 4593-4599.
Quinn, T. P., Peters, K. G., De Vries, C., Ferrara, N. and Williams, L. T.
(1993). Fetal liver kinase 1 is a receptor for vascular endothelial growth
factor and is selectively expressed in vascular endothelium. Proc. Natl.
Acad. Sci. USA 90, 7533-7637.
Ribelin, W. E. and Cox, J. R. (1965). The Pathology of Laboratory Animals.
Springfield: Charles C. Thomas.
Risau, W. (1995). Differentiation of endothelium. FASEB J. 9, 926-933.
Risau, W. (1997). Mechanisms of angiogenesis. Nature 386, 671-674.
Roberts, W. G. and Palade, G. E. (1995). Increased microvascular
permeability and endothelial fenestration induced by vascular endothelial
growth factor. J. Cell Sci. 108, 2369-2379.
Sage, E. H., Bassuk, J. A., Vost, J. C., Folkman, M. J. and Lane, T. F.
(1995). Inhibition of endothelial cell proliferation by SPARC is mediated
through a Ca (2+)-binding EF-hand sequence. J. Cell Biochem. 57, 127-
140.
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F.,
Breitman, M. L. and Schuh, A. C. (1995). Failure of blood-island
formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66.
Shalaby, F., Ho, J., Stanford, W. L., Fisher, K. D., Schuh, A. C., Schwartz,
L., Bernstein, A. and Rossant, J. (1997). A requirement for flk-1 in
primitive and definitive hematopoiesis. Cell 89, 981-990.
Vecchi, A., Garlanda, C., Lampugnani, M. G., Resnati, C., Matteucci, C.,
Stoppacciaro, A., Schnurch, H., Risau, W., Ruco, L., Mantovani, A. and
Dejana, E. (1994). Monoclonal antibodies specific for endothelial cells of
mouse blood vessels. Their application in the identification of adult and
embryonic endothelium. Eur. J. Cell Biol. 63, 247-254.
West, J. B. (1990). Physiological Basis of Medical Practice. Baltimore:
William and Wilkins.
Yuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N. and Jain, R.
K. (1996). Time-dependent vascular regression and permeability changes in
established human tumor xenografts induced by an anti-vascular endothelial
growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci.
USA 93, 14765-14770.
